Maximus (MMS) Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Maximus in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MMS shares.
View MMS analyst ratings or view top-rated stocks.

2 equities research analysts have issued twelve-month target prices for Maximus' shares. Their MMS share price forecasts range from $100.00 to $102.00. On average, they anticipate the company's stock price to reach $101.00 in the next year. This suggests a possible upside of 35.3% from the stock's current price.
View analysts price targets for MMS or view top-rated stocks among Wall Street analysts.

Maximus' stock was trading at $73.33 at the beginning of the year. Since then, MMS stock has increased by 1.8% and is now trading at $74.67.
View the best growth stocks for 2023 here.

Maximus saw a increase in short interest in August. As of August 15th, there was short interest totaling 1,310,000 shares, an increase of 26.0% from the July 31st total of 1,040,000 shares. Based on an average daily volume of 315,900 shares, the short-interest ratio is presently 4.1 days. Currently, 2.2% of the shares of the company are sold short.
View Maximus' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 20th 2023.
View our MMS earnings forecast.

Maximus, Inc. (NYSE:MMS) posted its quarterly earnings data on Wednesday, August, 2nd. The health services provider reported $0.78 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.14 by $0.36. The health services provider had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.20 billion. Maximus had a net margin of 3.56% and a trailing twelve-month return on equity of 15.11%. The firm's revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.78 EPS.

Maximus announced a quarterly dividend on Tuesday, July 11th. Stockholders of record on Tuesday, August 15th will be paid a dividend of $0.28 per share on Thursday, August 31st. This represents a $1.12 annualized dividend and a yield of 1.50%. The ex-dividend date is Monday, August 14th.
Read our dividend analysis for MMS.

ETFs with the largest weight of Maximus (NYSE:MMS) stock in their portfolio include Natixis Vaughan Nelson Mid Cap ETF (VNMC), ALPS O'Shares U.S. Small-Cap Quality Dividend ETF (OUSM), Fidelity Digital Health ETF (FDHT), Running Oak Efficient Growth ETF (RUNN), Nuveen Small Cap Select ETF (NSCS), iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV), Fidelity Low Volatility Factor ETF (FDLO) and First Trust Multi-Manager Small Cap Opportunities ETF (MMSC).

Maximus (NYSE:MMS) pays an annual dividend of $1.12 per share and currently has a dividend yield of 1.46%. The dividend payout ratio is 40.00%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, MMS will have a dividend payout ratio of 20.90% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MMS.

Maximus updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided EPS guidance of $3.74-$3.94 for the period, compared to the consensus EPS estimate of $3.09. The company issued revenue guidance of $4.88 billion-$4.97 billion, compared to the consensus revenue estimate of $4.95 billion.

145 employees have rated Maximus Chief Executive Officer Bruce Caswell on Glassdoor.com. Bruce Caswell has an approval rating of 80% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Maximus investors own include Pfizer (PFE), Lennar (LEN), AbbVie (ABBV), Cisco Systems (CSCO), Kroger (KR), Skyworks Solutions (SWKS), Advanced Micro Devices (AMD), Cerner (CERN), Intel (INTC) and JD.com (JD).

Maximus trades on the New York Stock Exchange (NYSE) under the ticker symbol "MMS."

Maximus' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.60%), Victory Capital Management Inc. (9.62%), Alliancebernstein L.P. (4.85%), Mackenzie Financial Corp (4.35%), State Street Corp (4.19%) and Geode Capital Management LLC (2.18%). Insiders that own company stock include Bruce Caswell, David Francis, David Mutryn, Ilene R Baylinson, Michael J Warren, Michelle F Link, Peter Pond, Raymond B Ruddy, Richard A Montoni, Richard A Montoni, Richard John Nadeau, Teresa Weipert, Thomas D Romeo and Thomas D Romeo.
View institutional ownership trends.

Shares of MMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MMS stock can currently be purchased for approximately $74.67.

Maximus (NYSE:MMS) has a market capitalization of $4.54 billion and generates $4.82 billion in revenue each year. The health services provider earns $203.83 million in net income (profit) each year or $2.80 on an earnings per share basis.

The company employs 39,500 workers across the globe.

Maximus' mailing address is 1891 METRO CENTER DRIVE, RESTON VA, 20190. The official website for the company is www.maximus.com. The health services provider can be reached via phone at (703) 251-8500, via email at investorrelations@maximus.com, or via fax at 703-251-8240.